Adial Pharmaceuticals welcomes Cary Claiborne to its Board of Directors

– USA, VA –  Adial Pharmaceuticals, Inc. (NASDAQ: ADIL/ADILW), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Cary Claiborne to its Board of Directors, increasing the number of board members to seven.

“We are honored to welcome Cary to the board of directors and believe he will be an important addition at this exciting time in our development, as we move closer to completion of our ONWARD Phase 3 trial of AD04 for the treatment of alcohol use disorder. Moreover, we believe his experience will be invaluable as we begin preparations for the commercial launch of AD04, assuming our trial is successful. We also look forward to his contributions as we seek to advance our Purnovate adenosine platform toward clinical trials, and potentially establish partnership opportunities. Given Cary’s impressive track record in finance and governance, we believe his appointment is a further illustration of our commitment to the highest levels of corporate governance.” said CEO, William Stilley. 

About Cary J. Claiborne

Mr. Claiborne previously served as CFO and board member of Indivior PLC, a publicly-traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses. Among his accomplishments, Mr. Claiborne led the company’s spin-off from its then parent company, Reckitt Benckiser, to become an independent, listed company. While at Indivior, he established and oversaw corporate reporting, internal audit, tax, treasury, external audit, and information technology.

Before joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt. Before joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc., and oversaw corporate finance during the company’s initial public offering. He graduated from Rutgers University with a B.A. in Business Administration and from Villanova University with an M.B.A. and was a National Association of Corporate Directors Governance Fellow.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder and is currently being investigated in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company’s proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing the frequency of drinking, the quantity of drinking and heavy drinking, and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity. The Company is also developing adenosine analogs for the treatment of pain and other disorders.

For more information:

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team